Skip to main content
SpringerLink
Log in

Diabetische Nephropathie

Gefäßprotektion durch Antidiabetika über die Glukosesenkung hinaus

  • Fortbildung
  • Diabetologie
  • Published:
CardioVasc Aims and scope

Makro- und mikrovaskuläre Folgeerkrankungen sind häufige Komplikationen bei Typ-2-Diabetikern. Die diabetische Nephropathie ist eine Komorbidität, die aufgrund neuer Studiendaten im Fokus steht. Bei der diabetischen Nephropathie besteht in Abhängigkeit vom Schweregrad eine lineare Assoziation mit kardiovaskulären Ereignissen, zudem ist sie die häufigste Ursache für eine Nierenersatztherapie.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Afkarian M, Sachs MC, Kestenbaum B et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24:302–8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Gregg EW, Li Y, Wang J et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370:1514–23

    Article  CAS  PubMed  Google Scholar 

  3. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–28

    Article  CAS  PubMed  Google Scholar 

  4. Marso SP, Daniels GH, Brown-Frandsen K et al. LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311–22

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Dormandy JA, Charbonnel B, Eckland DJ et al. PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89

    Article  CAS  PubMed  Google Scholar 

  6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65

    Article  Google Scholar 

  7. Wilding JPH. The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism. 2014;63:1228–37

    Article  CAS  PubMed  Google Scholar 

  8. Vasilakou D, Karagiannis T, Athanasiadou E et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med. 2013;159:262–74

    Article  PubMed  Google Scholar 

  9. Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34

    Article  CAS  PubMed  Google Scholar 

  10. Skrtic M, Yang GK, Perkins BA et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia. 2014;57:2599–602

    Article  PubMed  Google Scholar 

  11. Chilton R, Tikkanen I, Cannon CP et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17:1180–93

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Cherney DZ, Perkins BA, Soleymanlou N et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28

    Article  PubMed  PubMed Central  Google Scholar 

  13. Cherney DZ, Perkins BA, Soleymanlou N et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int. 2014;86:1057–8

    Article  CAS  PubMed  Google Scholar 

  14. Jordan J, Tank J, Heusser K et al. Empagliflozin has no discernable effect on muscle sympathetic nerve activity in patients with type 2 diabetes despite reductions in blood pressure and weight. Diabetes. 2014;63(Suppl 1):A265 (poster)

    Google Scholar 

  15. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin- receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60

    Article  CAS  PubMed  Google Scholar 

  16. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9

    Article  CAS  PubMed  Google Scholar 

  17. Parving H-H, Brenner BM, McMurray JJV et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–13

    Article  CAS  PubMed  Google Scholar 

  18. Brown NJ, Vaughan DE. Angiotensinconverting enzyme inhibitors. Circulation. 1998;97:1411–20

    Article  CAS  PubMed  Google Scholar 

  19. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59:251–87

    Article  CAS  PubMed  Google Scholar 

  20. Pfeffer MA, Claggett B, Diaz R et.al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247–57

    Article  CAS  PubMed  Google Scholar 

  21. Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol. 2014;10:88–103

    Article  CAS  PubMed  Google Scholar 

  22. Tanaka T, Higashijima Y, Wada T, Nangaku M. The potential for renoprotection with incretin-based drugs. Kidney Int. 2014;86:701–11

    Article  CAS  PubMed  Google Scholar 

  23. Bisgaard LS, Bosteen MH, Fink LN et al. Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice. PLoS One. 2016;11(12):e0168396

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Isar Klinikum München GmbH, Klinik für Endokrinologie, Diabetologie und Stoffwechsel, Sonnenstraße 24–26, 80331, München, Deutschland

    Thorsten Siegmund

Authors
  1. Thorsten Siegmund
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thorsten Siegmund.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Siegmund, T. Gefäßprotektion durch Antidiabetika über die Glukosesenkung hinaus. CV 17, 43–46 (2017). https://doi.org/10.1007/s15027-017-1144-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-017-1144-7

Search

Navigation